Latigo Biotherapeutics, Inc. (LTGO) News
Follow Latigo Biotherapeutics, Inc. (LTGO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
LTGO’s Onzotrigine shows rapid, superior acute pain relief in late-stage trials
TradingView News reports Onzotrigine (LTGO) is in late-stage trials for acute pain, citing superior efficacy, rapid onset and opioid-sparing potential. It also notes LTG-321 is progressing in chronic pain.
EQUITY | Sep 03, 2026, 09:42 PM UTC
L
Latigo (LTGO) upsizes IPO to $397.4M, extends cash runway
Latigo Biotherapeutics upsized its IPO to $397.4 million, extending its cash runway into 2029. Phase 2 results for onzotrigine in acute pain were published in NEJM; Phase 3 trials are planned.
EARNINGS | Sep 03, 2026, 08:46 PM UTC
M
Latigo Biotherapeutics reports 2Q loss of $25.8M
Latigo Biotherapeutics posted a 2Q loss of $25.8M.
EQUITY | Sep 03, 2026, 08:19 PM UTC
M
Latigo Biotherapeutics reports 2Q loss per share of $27.59
Latigo Biotherapeutics said it posted a 2Q loss of $27.59 per share.
EQUITY | Sep 03, 2026, 08:19 PM UTC
L
Latigo projects cash and cash equivalents to fund plans through 2029
Latigo says cash and cash equivalents are projected to fund operating plans into 2029.
EQUITY | Sep 03, 2026, 08:19 PM UTC
L
Latigo Biotherapeutics reports Q2 2026 financial results
Latigo Biotherapeutics reported its second-quarter 2026 financial results and recent business highlights.
EARNINGS | Sep 03, 2026, 08:05 PM UTC
L
Leerink sets $36 price target for Latigo Biotherapeutics
Latigo Biotherapeutics was initiated at an Outperform rating by Leerink Partners, with a $36.00/share price target announced, per TradingView News.
EQUITY | Sep 01, 2026, 06:47 PM UTC
L
Jefferies sets $50 price target on Latigo Biotherapeutics
Jefferies announced a $50.00/share price target for Latigo Biotherapeutics.
EQUITY | Sep 01, 2026, 06:18 PM UTC
L
Latigo Biotherapeutics started at Buy by Guggenheim
Guggenheim initiated coverage on Latigo Biotherapeutics with a Buy rating.
EQUITY | Sep 01, 2026, 12:51 PM UTC